公开(公告)号：US20240277758A1

公开(公告)日：2024-08-22

申请号：US18397569

申请日：2023-12-27

Applicant: Hope Medical Enterprises, Inc. DBA Hope Pharmaceuticals

Inventor： Craig Sherman ,  Micah Bodner ,  Jon Marshall

IPC: A61K33/04 ,  A61K9/00 ,  A61K31/717

CPC classification number: A61K33/04 ,  A61K9/0014 ,  A61K31/717

Abstract: Provided herein are formulations comprising sodium thiosulfate. Also provided herein are methods of treating, preventing or ameliorating a sulfur mustard skin injury in a subject, wherein the methods comprise contacting the subject with a formulation provided herein.

公开(公告)号：US20240165046A1

公开(公告)日：2024-05-23

申请号：US18282545

申请日：2022-01-28

Applicant: Aalto University Foundation sr

Inventor： Jani Kuula ,  Eija Raussi-Lehto ,  Orlando Rojas ,  Rubina Ajdary ,  Tomi Mikkola

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/717 ,  A61L27/20 ,  A61L27/54

CPC classification number: A61K9/70 ,  A61K9/0024 ,  A61K31/717 ,  A61L27/20 ,  A61L27/54 ,  A61L2300/412 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2400/12 ,  A61L2430/22 ,  A61L2430/34

Abstract: According to an example aspect of the present invention, there is provided a composition for use in the treatment of urinary or faecal incontinence, the composition comprising a nanostructured cellulosic material.

公开(公告)号：US11944703B2

公开(公告)日：2024-04-02

申请号：US18365024

申请日：2023-08-03

Applicant: Clearside Biomedical, Inc.

Inventor： Ronald Yamamoto ,  Stanley R. Conston ,  David Sierra

IPC: A61F9/007 ,  A61F9/00 ,  A61K9/00 ,  A61K9/16 ,  A61K31/717 ,  A61K31/718 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/36 ,  A61M5/31 ,  A61M5/48 ,  A61K9/14

CPC classification number: A61K9/0048 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/007 ,  A61F9/00736 ,  A61K9/0051 ,  A61K9/1635 ,  A61K31/717 ,  A61K31/718 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/36 ,  A61M5/486 ,  A61K9/14 ,  A61M2005/3103 ,  A61M2210/0612

Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the suprachoroidal space (SCS). The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.

公开(公告)号：US11752101B2

公开(公告)日：2023-09-12

申请号：US17711495

申请日：2022-04-01

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Ronald Yamamoto ,  Stanley R. Conston ,  David Sierra

IPC: A61F9/007 ,  A61F9/00 ,  A61M5/31 ,  A61K9/00 ,  A61K9/16 ,  A61K31/717 ,  A61K31/718 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/36 ,  A61M5/48 ,  A61K9/14

CPC classification number: A61K9/0048 ,  A61F9/007 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/00736 ,  A61K9/0051 ,  A61K9/1635 ,  A61K31/717 ,  A61K31/718 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/36 ,  A61M5/486 ,  A61K9/14 ,  A61M2005/3103 ,  A61M2210/0612

Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.

公开(公告)号：US20230270799A1

公开(公告)日：2023-08-31

申请号：US18004082

申请日：2021-07-01

Applicant: UNIVERSIDAD DE GRANADA

Inventor： José Manuel DOMÍNGUEZ VERA ,  José Manuel DELGADO LÓPEZ ,  Ana GONZÁLEZ GARNICA ,  Gloria Belén RAMIREZ RODRIGUEZ ,  Natividad GÁLVEZ RODRÍGUEZ ,  Laura SABIO RODRÍGUEZ

IPC: A61K35/747 ,  A61P31/04 ,  A61K35/745 ,  A01N63/20 ,  A01N43/16 ,  A61K31/717 ,  C12N1/20 ,  A23P20/10 ,  A23L33/135 ,  C12N11/04

CPC classification number: A61K35/747 ,  A61P31/04 ,  A61K35/745 ,  A01N63/20 ,  A01N43/16 ,  A61K31/717 ,  C12N1/20 ,  A23P20/105 ,  A23L33/135 ,  C12N11/04 ,  A23Y2220/35 ,  A23Y2220/37

Abstract: The invention relates to biomaterials, which comprise a bacterial cellulose matrix and probiotics entrapped in said bacterial cellulose. The invention also relates to methods for obtaining the biomaterial, as well as uses of the biomaterial in medicine. It also relates to coated food products wherein the coat is composed of said biomaterial wherein the coat acts to prevent the proliferation of undesired bacteria. It also relates to packaged medical devices, wherein the package comprises said biomaterial also preventing growth of pathogenic bacteria.

公开(公告)号：US20230263818A1

公开(公告)日：2023-08-24

申请号：US18309440

申请日：2023-04-28

Applicant: Otsuka Pharmaceutical Co., Ltd.

Inventor： Aram Oganesian ,  Nipun Davar ,  Jim Hwaicher Kou

IPC: A61K31/706 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/20 ,  A61K31/7016 ,  A61K31/717

CPC classification number: A61K31/706 ,  A61K9/0056 ,  A61K9/20 ,  A61K9/4891 ,  A61K31/20 ,  A61K31/7016 ,  A61K31/717

Abstract: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.

公开(公告)号：US20230174679A1

公开(公告)日：2023-06-08

申请号：US17806323

申请日：2022-06-10

Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Inventor： MARK H. SCHOENFISCH ,  MONA JASMINE R. AHONEN ,  LEI YANG ,  HAIBAO JIN ,  EVAN SCOTT FEURA ,  SARA ELIZABETH MALONEY

IPC: C08B15/04 ,  C08B37/08 ,  C08B37/00 ,  A61K9/06 ,  A61K31/717 ,  A61K31/726 ,  A61L27/34 ,  A61K31/728

CPC classification number: C08B15/04 ,  C08B37/0072 ,  C08B37/0063 ,  A61K9/06 ,  A61K31/717 ,  A61K31/726 ,  A61L27/34 ,  A61K31/728 ,  A61L2300/404

Abstract: Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.

公开(公告)号：US20180185406A1

公开(公告)日：2018-07-05

申请号：US15908274

申请日：2018-02-28

Applicant: Joshua D. Levine ,  Robert A. Levine

Inventor： Joshua D. Levine ,  Robert A. Levine

IPC: A61K31/717 ,  A61K47/38 ,  A61K9/00 ,  A61K9/12

CPC classification number: A61K31/717 ,  A61K9/0043 ,  A61K9/12 ,  A61K47/38

Abstract: A composition for use in a nasal application, the composition including an aqueous carrier and a viscosity agent. The viscosity agent is in the range of about 4% to about 15% by weight. The viscosity agent is in solution with the aqueous carrier. The solution of the aqueous carrier and the viscosity agent is configured as a thixotropic composition.

公开(公告)号：US09962374B2

公开(公告)日：2018-05-08

申请号：US15177760

申请日：2016-06-09

Applicant: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.

Inventor： Juan Armendáriz Borunda ,  José Agustín Rogelio Magaña Castro ,  Jorge Cervantes Guadarrama

IPC: A61K9/22 ,  A61K31/715 ,  A61K31/435 ,  A61K31/4418 ,  A61K9/20 ,  A61K31/4412 ,  A61K9/00 ,  A61K31/717 ,  A61K31/44

CPC classification number: A61K31/4418 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/717

Abstract: The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

公开(公告)号：US09826768B2

公开(公告)日：2017-11-28

申请号：US14771891

申请日：2014-04-08

Applicant: Dow Global Technologies LLC

Inventor： Puspendu Deo ,  Kathryn Brown ,  David E. Wallick ,  Robert L. Sammler ,  Yongfu Li

IPC: A61K31/717 ,  C08L1/28 ,  C08J3/03 ,  A23L1/308 ,  C08J3/075 ,  A23L29/262 ,  A23L33/24

CPC classification number: A23L29/262 ,  A23L33/24 ,  A23V2002/00 ,  A61K31/717 ,  C08J3/03 ,  C08J3/075 ,  C08J2301/28 ,  C08L1/28

Abstract: A process for preparing an aqueous solution of a methylcellulose having anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups, comprises the step of mixing the methylcellulose with an aqueous liquid at a temperature of not higher than 10° C. at a shear rate of at least 1000 s−1.